全身炎症在晚期慢性肝病不同阶段逐渐加重,并与失代偿和死亡相关
该单中心前瞻性队列纳入2017年1月至2019年8月接受肝静脉压力梯度(HVPG)测量的晚期慢性肝病(ACLD)患者168例,按6个预后阶段分组。结果显示MELD在各阶段均升高,HVPG主要在代偿期亚组升高,CRP和IL-6仅在失代偿期亚组显著升高;IL-6是代偿期患者1年失代偿的独立预测因子,也预测失代偿期患者1年死亡/移植。
要点
- HVPG进展主要见于代偿期ACLD患者,而全身炎症(以IL-6反映)仅在失代偿期各阶段显著升高。
- 代偿期ACLD中,IL-6是1年失代偿的独立预测因子(HR 1.06,95%CI 1.01-1.10;p=0.013)。
- 失代偿期ACLD中,IL-6预测1年随访后的死亡/移植(HR 1.02,95%CI 1.01-1.03;p=0.004)。
核心结论
- HVPG进展主要发生在代偿期ACLD患者,而全身炎症(以IL-6水平反映)仅在失代偿期各阶段显著升高。
- IL-6水平与代偿期ACLD首次失代偿风险及失代偿期ACLD死亡/移植风险相关。
研究设计与样本
- 单中心前瞻性队列研究,纳入2017年1月至2019年8月接受HVPG测量的ACLD患者168例。
- 按6个预后阶段分类:轻度门脉高压(HVPG 6-9 mmHg,S0)、临床显著门脉高压(HVPG≥10 mmHg无静脉曲张,S1)、存在静脉曲张(S2)、静脉曲张出血史(S3)、首次非出血性失代偿(S4)、进一步失代偿(S5)。
- 评估MELD、CRP和IL-6水平对失代偿和死亡的预测价值。
主要发现
- 168例ACLD患者中,代偿期78例(S0=13;S1=21;S2=44),失代偿期90例(S3=10;S4=58;S5=22)。
- MELD在所有阶段均升高(p<0.001),而HVPG主要在代偿期亚组内升高。
- CRP和IL-6水平的显著升高仅见于失代偿期亚组。
- 代偿期ACLD中,IL-6是1年随访时失代偿的独立预测因子(HR 1.06,95%CI 1.01-1.10;p=0.013)。
- 失代偿期ACLD中,IL-6水平预测1年随访后的死亡/移植(HR 1.02,95%CI 1.01-1.03;p=0.004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Distinct prognostic stages of advanced chronic liver disease (ACLD) are defined by severity of portal hypertension (PH) and the presence/absence of clinical complications. We characterised the degree of liver dysfunction, PH, and systemic inflammation across the distinct prognostic stages and assessed their relative impact on decompensation and mortality. METHODS: A single-centre, prospective cohort of ACLD patients undergoing hepatic venous pressure gradient (HVPG) measurement between 01/2017 and 08/2019 were classified into 6 prognostic stages: mild PH (HVPG 6-9 mmHg, S0), clinically significant PH (HVPG ≥10 mmHg without varices, S1), presence of varices (S2), history of variceal bleeding (S3), first non-bleeding decompensation (S4), and further decompensation (S5). The model for end-stage liver disease (MELD), C-reactive protein (CRP), and IL-6 levels were assessed in relation to their predictive value for decompensation and death. RESULTS: Among 168 ACLD patients 78 had compensated (cACLD, S0 = 13; S1 = 21; S2 = 44) and 90 had decompensated (dACLD, S3 = 10; S4 = 58; S5 = 22) disease. MELD increased across all stages (p <0.001), whereas HVPG mostly increased within cACLD substages. Significant increases in CRP and IL-6 levels were only noted across dACLD substages. IL-6 was an independent predictor of decompensation at 1-year follow-up in cACLD (hazard ratio [HR] 1.06, 95% CI 1.01-1.10; p = 0.013). In dACLD patients, IL-6 levels predicted death/transplantation after 1-year of follow-up (HR 1.02, 95% CI 1.01-1.03; p = 0.004). CONCLUSION: HVPG progression occurs mostly in cACLD patients, whereas systemic inflammation, as reflected by IL-6 levels, only increases substantially across dACLD stages. IL-6 levels correlate with the risk of first decompensation in cACLD and of death/transplantation in dACLD patients. LAY SUMMARY: Patients with advanced chronic liver disease (ACLD; i.e. liver cirrhosis) have a certain risk of mortality according to their stage of disease. Progression of disease is greatly influenced by increased pressure in the portal venous system (i.e. portal hypertension) and occurrence of clinical complications (i.e. decompensation). Our study demonstrates that systemic inflammation markedly increases across highest disease stages, and the inflammation biomarker IL-6 in blood may specifically indicate risk of disease progression in patients with ACLD. CLINICAL TRIALS REGISTRATION: The study is registered at ClinicalTrials.gov (NCT03267615).
引用
- Costa D, Simbrunner B, Jachs M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2020. PMID: 33075344. doi:10.1016/j.jhep.2020.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。